Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Capital Expenditures (2020 - 2023)

Cullinan Therapeutics (CGEM) has 3 years of Capital Expenditures data on record, last reported at $49000.0 in Q2 2023.

  • For Q2 2023, Capital Expenditures changed N/A year-over-year to $49000.0; the TTM value through Dec 2023 reached $208000.0, down 81.64%, while the annual FY2025 figure was $49000.0, N/A changed from the prior year.
  • Capital Expenditures reached $49000.0 in Q2 2023 per CGEM's latest filing, down from $159000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $882000.0 in Q4 2022 and bottomed at -$1000.0 in Q4 2020.
  • Average Capital Expenditures over 3 years is $168875.0, with a median of $26500.0 recorded in 2020.